Singapore markets closed
Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
62,700.21 +3,753.26 (+6.37%) CMC Crypto 200
1,363.86 +86.88 (+6.80%)
Propanc Biopharma, Inc. (PPCB)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 03:03PM EDT
| Previous close | 0.0008 |
| Open | 0.0008 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0007 - 0.0008 |
| 52-week range | 0.0001 - 0.2625 |
| Volume | |
| Avg. volume | 4,532,720 |
| Market cap | 41,716 |
| Beta (5Y monthly) | 1.69 |
| PE ratio (TTM) | 0.00 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Propanc Biopharma Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent Office
MELBOURNE, Australia, April 16, 2024--The PRP dosing patent is an important part of our IP portfolio, as we seek to protect our novel invention and create future value for our shareholders
- Business Wire
Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing
MELBOURNE, Australia, April 08, 2024--Mr. Nathanielsz appeared on a show with Mr. Joel Block, a weekly podcast on killer business strategies and how the best leaders make them work
- Business Wire
Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study
MELBOURNE, Australia, February 22, 2024--The compassionate use study results highlight clinical effects studied in 46 patients with advanced metastatic cancers of different origin
© 2024 Yahoo. All rights reserved.